Medac Pharma has appointed Kirk Chester as national account manager for the organisation’s newest hepatic oncology product, Chemosat.

Kirk brings with him to the business 18 years’ experience in the pharmaceutical industry and an extensive knowledge of both secondary and primary care, which will be "key to medac’s continued growth plans for its portfolio of oncology products."

Having previously worked for Novartis, Teva and GSK, Kirk has worked within many healthcare sectors including oncology, ophthalmology, men’s health and urology.

He is "delighted to join medac Pharma to promote Chemosat, which is an exciting and innovative therapy that can help people with inoperable liver cancer, a disease which previously had few treatment options.”

Managing director, Alastair McMurray, commented: “We are delighted that Kirk has joined the company and his appointment will be pivotal in driving the company’s growth as we strive to be a global player in the field of oncology.”